Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolised Liposomal Ciclosporin A for BOS Prevention in Lung Transplant
NCT01334892Phase 3Terminated
- Sponsor
- PARI Pharma
- Start
- Dec 2009
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Cyclosporine Inhalation Solution in Bronchiolitis Obliterans Syndrome (BOS) (2 arms), sponsored by PARI Pharma. Primary endpoint: Cumulative BOS-free survival at 2 years. Started Dec 2009; status: terminated.
02
Drugs
Cyclosporine Inhalation Solution
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT01334892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01334892.